<SEC-DOCUMENT>0001062993-18-002475.txt : 20180604
<SEC-HEADER>0001062993-18-002475.hdr.sgml : 20180604
<ACCEPTANCE-DATETIME>20180604140356
ACCESSION NUMBER:		0001062993-18-002475
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20180528
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180604
DATE AS OF CHANGE:		20180604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		18877618

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>May 28,
2018</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="33%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="33%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code<B><U>(250) 765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>[&nbsp;&nbsp; ]&nbsp;&nbsp; Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))<BR>[&nbsp;&nbsp; ]&nbsp;&nbsp; Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))<BR></P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp; ] </P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.</P>
<P align=right> [&nbsp;&nbsp; ]</P>
<P align=justify><B>Item 1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Entry
into a Material Definitive Agreement </B></P>
<P align=justify>On May 28, 2018, Lexaria Bioscience Corp. ("Lexaria" or the
"Company") announced that is has entered into a three-year consulting contract
with Nuka Enterprises, LLC ("Nuka") for the cost of a one-time payment of US$500
(the "Consulting Agreement"). The services to be provided by Nuka include customer relations and introductions, participation at industry
events and the communication of Lexaria's technology to other prospective
customers. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify><B>Item 3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Unregistered Sales of Equity Securities </B></P>
<P align=justify>Lexaria has received US$63,000<B> </B>from the exercise of
warrants previously granted. The Company has received for exercise a total of
450,000 warrants with an exercise price of US$0.14, previously granted. The
warrant exercises are by third parties who are neither an officer nor a director
of the Company. No commissions or placement fees have been paid related to the
funds received from these warrants exercised. Proceeds will be used for general
corporate purposes.</P>
<P align=justify><B>The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. </B></P>
<P align=justify>The Company granted 250,000 warrants expiring three years after
issuance with an equity exercise price of US$1.55 to Nuka pursuant to the
Consulting Agreement. </P>
<P align=justify>Company announced that pursuant to existing stock option plans,
it has granted stock options to directors, officers, employees and consultants
that enable the option holders to purchase up to 1,725,000 common shares of the
Company at a price of US$1.53 for a period of five years, vesting immediately.
</P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news releases announcing that Lexaria has
received US$63,000<B> </B>from the exercise of warrants previously granted and
that Lexaria has entered into the Consulting Agreement is filed as exhibit 99.1
to this current report and is hereby incorporated by reference.</P>
<P align=justify>A copy of the news releases announcing that Lexaria intends to
create two wholly-owned subsidiaries is filed as exhibit 99.2 to this current
report and is hereby incorporated by reference.</P>
<P align=justify><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Financial Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit10-1.htm">10.1 </a></TD>
    <TD bgColor=#eeeeee >
  <P align=justify><a href="exhibit10-1.htm">Consulting Agreement with Nuka Enterprises, LLC</a></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD bgColor=#eeeeee >
      <P align=justify><a href="exhibit99-1.htm">Press Release dated May 28, 2018</a></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit99-2.htm">99.2 </a></TD>
    <TD bgColor=#eeeeee >
      <P align=justify><a href="exhibit99-2.htm">Press Release dated May 31, 2018</a></P></TD></TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify>&nbsp;</P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date: June 1, 2018 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 10.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><U>CONSULTING SERVICES AGREEMENT</U></B><B> </B></P>
<P align=justify>THIS CONSULTING SERVICES AGREEMENT (this &#147;<B>Agreement</B>&#148;)
dated for reference the 25<SUP>th</SUP> day of May, 2018. </P>
<P align=justify>BETWEEN: </P>
<blockquote>
  <blockquote>
    <blockquote>
      <blockquote>
        <p align="justify"><B>Lexaria Bioscience Corp.,</B> a company duly incorporated
          under the laws of the State of Nevada and having its office at 156 Valleyview
          Rd, Kelowna BC Canada V1X 3M4 </p>
        <p align="justify">(hereinafter referred to as the &#147;<B>Company</B>&#148;) </p>
      </blockquote>
    </blockquote>
  </blockquote>
</blockquote>
<P align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OF THE FIRST PART </P>
<P align=justify>AND </P>
<blockquote>
  <blockquote>
    <blockquote>
      <blockquote>
        <p align="justify"><B>Nuka Enterprises, LLC</B>, a Delaware<B> </B>limited
          liability company with offices at 9690 Dallas St., Henderson, Colorado
          (hereinafter referred to as "the <B>Consultant</B>" or &#147;<B>Consultant</B>&#148;) </p>
      </blockquote>
    </blockquote>
  </blockquote>
</blockquote>
<P align=justify><B>WHEREAS</B>: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">A. </TD>
    <TD>
      <P align=justify>The Company wishes to engage Consultant as its external
      technology, partnering and branding liaison, reporting to the CEO and
      President of the Company, and assorted other opportunities on the terms
      and conditions hereinafter set forth, effective May 25, 2018 (the
      &#147;<B>Effective Date</B>&#148;).</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">B. </TD>
    <TD>
      <P align=justify>Consultant has agreed to provide the Services (as
      hereinafter defined) to the Company on the terms and conditions set out in
      this Agreement.</P></TD></TR></TABLE>
<P align=justify>NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of
the premises and of the covenants and agreements hereinafter contained the
parties hereto have agreed as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify><B><U>ENGAGEMENT OF
SERVICES</U></B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">1.1. </TD>
    <TD>
      <P align=justify>The Company hereby engages Consultant to provide Services
      as an independent contractor to the Company under the direction of the CEO
      and President of the Company; and</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">1.2. </TD>
    <TD>
      <P align=justify>Consultant hereby agrees to perform the following duties
      required of it in accordance with the terms of this Agreement,
    namely:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Promote the Company and its technology at public events;
      conferences; industry events and in private corporate or industry-related
      discussions; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>Act as ambassador and promote a positive image about the
      Company to the press and news media when there are opportunities to do so;
      and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify><U>General Services</U>. Consultant shall serve the
      Company (and/or such subsidiary or subsidiaries of the Company as the
      Company may from time to time reasonably require) in such consulting
      capacity or capacities as may from time to time be determined by senior
      management of the Company and shall perform such duties and exercise such
      powers as may from time be determined by senior Company management, as an
      independent contractor. Consultant will work as needed with partners,
      shareholders and other stakeholders as reasonably required by the Company.
      Consultant shall fulfill all duties expected of a senior consultant of a
      biotechnology/bioscience company that should be reasonably expected by and
      at the pleasure of the Board of Directors of the Company (together with
      all other items within Section 1.2, the
  &#147;<B>Services</B>&#148;).</P></TD></TR></TABLE>
<P align=center>- 1 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify><B><U>TERM</U></B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">2.1. </TD>
    <TD>
      <P align=justify>The initial term of this Agreement shall be for a period
      of three (3) years commencing as of the Effective Date and continuing
      thereafter until the third (3<SUP>rd</SUP>) anniversary of the Effective
      Date, with all terms in effect unless and until terminated as hereinafter
      provided in Section 5.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">2.2. </TD>
    <TD>
      <P align=justify>Unless earlier terminated or renewed with a new
      agreement, this Agreement will remain in force on a month-to-month basis
      upon its expiry, provided however that Consultant shall be compensated for
      any additional Services as mutually agreed upon by the
  parties.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify><B><U>SERVICES</U></B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">3.1 </TD>
    <TD>
      <P align=justify>Consultant agrees to perform the Services contracted
      hereunder including the following:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>to carry out all functions associated with the Services
      to the best of its skill and ability for the benefit of the
  Company;</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>to carry out the Services in a timely manner;</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>to NOT perform the same work or engage in the same
      services for any other company or client that provides technology that
      directly competes against the Company for gastro-intestinal delivery
      benefits or topical delivery benefits;</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>to act, at all times during the term of this Agreement,
      in the best interests of the Company and to not participate in any
      activity to the material detriment of the Company or its reputation; and
      to use its commercially reasonable efforts to preserve the goodwill and
      positive reputation of the Company.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify><B><U>REMUNERATION</U></B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top align=left width="5%">
      <P align=justify>4.1. </P></TD>
    <TD align=left>
      <P align=justify><U>Cash Compensation</U>. In addition to the compensation
      set forth herein, the Company shall pay to Consultant for all Services
      rendered hereunder the sum of five-hundred dollars
  <B>(US$500).</B></P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4.2. </TD>
    <TD>
      <P align=justify><U>Expenses</U>. Consultant shall be reimbursed for
      travelling and other expenses actually incurred by it in connection with
      its duties and Services hereunder only when approved in advance by Company
      and on an individualized basis. For all such expenses, Consultant shall
      furnish to the Company statements, receipts and vouchers for such
      out-of-pocket expenses within 30-days of occurrence.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4.3. </TD>
    <TD>
      <P align=justify><U>Equity Compensation</U>.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Upon each and any time, between the Effective Date and
      the first (1<SUP>st</SUP>) anniversary of the Effective Date, that the
      Company&#146;s revenues from any single customer of the Company
      introduced/developed or managed by Consultant in any consecutive 60-day
      period during such annual period equals or exceeds US$400,000 for combined
      &#147;Lexaria Energy&#148; and &#147;ViPova&#148; products and including all combined sales
      efforts and/or technology licensing revenues, the Company shall grant
      Consultant a restricted common share award of 75,000 shares of the
      Company&#146;s Common Stock; and</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>Upon each and any time, after the first (1<SUP>st</SUP>)
      anniversary of the Effective Date and expiring twenty-four (24) months of
      the Effective Date, that the Company&#146;s revenues from any single customer
      of the Company introduced/developed or managed by Consultant in any
      consecutive 60-day period equals or exceeds US$400,000 for combined
      &#147;Lexaria Energy&#148; and &#147;ViPova&#148; products and including all sales efforts
      and/or technology licensing revenues, the Company shall grant Consultant a
      restricted common share award of 40,000 shares of the Company&#146;s
  Common Stock; and</P></TD></TR></TABLE>
<P align=center>- 2 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>Upon each and any time, between the Effective Date and
      the first (1<SUP>st</SUP>) anniversary of the Effective Date, that the
      Company&#146;s revenues in any fiscal quarter during such annual period, equals
      or exceeds US$800,000 for combined &#147;Lexaria Energy&#148; and &#147;ViPova&#148; products
      and including all sales efforts and/or technology licensing revenues
      introduced/developed or managed by Consultant, the Company shall grant
      Consultant a restricted common share award of 150,000 shares of the
      Company&#146;s Common Stock; and</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>Upon each and any time, after the first (1<SUP>st</SUP>)
      anniversary of the Effective Date and expiring twenty-four (24) months of
      the Effective Date, that the Company&#146;s revenues in any fiscal quarter
      during such annual period, equals or exceeds US$800,000 for combined
      &#147;Lexaria Energy&#148; and &#147;ViPova&#148; products and including all sales efforts
      and/or technology licensing revenues introduced/developed or managed by
      Consultant, the Company shall grant Consultant a restricted common share
      award of 80,000 shares of the Company&#146;s Common
Stock.</P></TD></TR></TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">4.4. </TD>
    <TD>
      <P align=justify>Upon the Effective Date of this Agreement and subject to
      approval of all regulatory bodies, the Company shall grant Consultant a
      warrant for 250,000 common shares of the Company with a three-year
      expiration and a strike price equal to one-cent above the previous day&#146;s
      closing price (in U.S. dollars) (the &#147;<B>Warrant</B>&#148;). The Warrant, if at
      that time unexercised, will expire immediately if Company terminates this
      Agreement pursuant to Section 5.2 below. For the avoidance of doubt, if
      Company terminates this Agreement without cause or reason, the Warrant
      shall not expire until its scheduled three-year
  expiration.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">4.5. </TD>
    <TD>
      <P align=justify>Sections 4.3 and 4.4 above, collectively or individually,
      are defined as &#147;<B>Milestone Payments</B>&#148;. Should the Company terminate
      this Agreement without cause or reason pursuant to Section 5.1 below,
      Consultant will be entitled to all Milestone Payments, as they relate to
      transactions which were in process but had not yet closed at the effective
      date of termination. Any and all awards granted pursuant to this Section
      4, including without limitation the Warrant and restricted common stock
      awards shall be deemed fully vested when granted and shall not be subject
      to any repurchase rights or forfeiture, regardless of whether or not this
      Agreement is terminated.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify><B><U>TERMINATION</U></B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">5.1. </TD>
    <TD>
      <P align=justify>This Agreement may be terminated by either party at any
      time by sixty (60) days&#146; notice in advance, in writing given by Consultant
      to the Company, or by the Company to Consultant.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5.2. </TD>
    <TD>
      <P align=justify>Either party may terminate this Agreement, at any time,
      without further obligation to the other party, if such party breaches any
      of the terms and conditions of this Agreement, including, but not limited
      to, if:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>The Company or Consultant shall commit any material
      breach of any of the provisions herein contained; or</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>The Company or Consultant shall be guilty of any willful
      misconduct or negligence in the discharge of its duties hereunder;
    or</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>The Company or Consultant shall become bankrupt or make
      any assignments for the benefit of its creditors;
or</P></TD></TR></TABLE>
<P align=center>- 3 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD>
      <P align=justify>The Consultant shall be convicted of any felony offence
      other than an offence which, in the reasonable opinion of the Board of
      Directors of the Company, does not affect Consultant&#146;s position as a
      Consultant of the Company; or</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD>
      <P align=justify>The Company shall be convicted of any criminal offence
      other than an offence which, in the reasonable opinion of the Consultant,
      does not affect Consultant&#146;s position as a Consultant of the
    Company.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">5.3 </TD>
    <TD>
      <P align=justify>The provisions of Sections 8.4 and 8.5 (Proprietary
      Information and on Confidentiality) shall survive the termination or
      expiration of this Agreement.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5.4 </TD>
    <TD>
      <P align=justify>Upon Termination or expiration of this Agreement, for any
      reason, Consultant must destroy, or return to the Company immediately, any
      correspondence, information, reports, emails, phone recordings or
      transcripts, notes, Consultant contact information and all other materials
      related to all non-public work performed for the Company including all
      Proprietary Information during the term of the Agreement. All such
      materials and information as referred to in this Section 5.4, are the
      exclusive property of the Company. After returning, transmitting or
      otherwise sending such information to the Company, Consultant must destroy
      any and all remaining copy(ies) or records of same. Investor lists, banker
      and broker lists, and shareholder lists whether provided by the Company or
      developed by Consultant, if used by Consultant during activities provided
      under this Agreement, are the exclusive property of the Company any may
      not be used nor contacted in any manner by the Consultant for any non-
      Company purpose either during the term of this Agreement and for two (2)
      years following the expiration of this Agreement. All such materials and
      information obtained during the term of this Agreement may not be shown,
      downloaded, lent, given, discussed or in any way disclosed with or to any
      other party subject to the terms of this Agreement. The Proprietary
      Information Consultant gained or has access to during the term of this
      Agreement is the exclusive property of the Company, and the provisions
      governing such proprietary information survives the termination of this
      Consulting Agreement.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify><B><U>NOTICE </U></B>Any notice to be given under this
      Agreement shall be in writing and shall be deemed to have been given if
      delivered to, or sent by email, personal delivery or prepaid registered
      post addressed to, the respective addresses of the parties appearing on
      the first page of this Agreement (or to such other address as one party
      provides to the other in a notice given according to this paragraph).
      Where a notice is given by registered post it shall be conclusively deemed
      to be given and received on the fifth day after its deposit in a Canada
      post office any place in Canada.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">7. </TD>
    <TD>
      <P align=justify><B><U>TAXES </U></B>Consultant shall be responsible for
      the payment of its income, capital gains and all other taxes and other
      remittances including but not limited to any form of insurance as shall be
      required by any governmental entity (including but not limited to health
      insurance and federal and state or provincial income taxes), though not
      including Director&#146;s and Officer&#146;s insurance which is paid for and
      provided by the Company, with respect to compensation paid by the Company
      to Consultant, and nothing in this Agreement implies or creates a
      relationship of employment. Consultant agrees to indemnify the Company for
      any tax, insurance or other remittance Consultant fails to make and which
      the Company may be obligated to pay.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8. </TD>
    <TD>
      <P align=justify><B><U>MISCELLANEOUS</U></B></P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">8.1 </TD>
    <TD>
      <P align=justify>This Agreement may not be assigned by either party
      without the prior written consent of the other.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.2 </TD>
    <TD>
      <P align=justify>The titles of headings to the respective paragraphs of
      this agreement shall be regarded as having been used for reference and
      convenience only.</P></TD></TR></TABLE>
<P align=center>- 4 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_5></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">8.3 </TD>
    <TD>
      <P align=justify>This Agreement shall inure to the benefit of and be
      binding upon the parties hereto and their respective heirs, executors,
      administrators, successors and permitted assigns.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.4 </TD>
    <TD>
      <P align=justify>Consultant shall not, either during the continuance of
      its contract hereunder and for a period of two (2) years after termination
      of this Agreement, disclose the private affairs of the Company and/or its
      subsidiary or subsidiaries, or any secrets or intellectual property of the
      Company (together or separately and as described below, &#147;<B>Proprietary
      Information</B>&#148;) and/or its subsidiary or subsidiaries, to any person
      other than the Directors of the Company and/or its subsidiary or
      subsidiaries or for the Company's purposes or for the performance of
      fulfilling its obligations hereunder and shall not (either during the
      continuance of its contract hereunder and for a period of three (3) years
      after termination of this Agreement) use for its own purposes or for any
      purpose other than those of the Company any information it may acquire in
      relation to the business and affairs of the Company and/or its subsidiary
      or subsidiaries, unless required by law or as necessary to perform its
      obligations hereunder.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.5 </TD>
    <TD>
      <P align=justify><B>Proprietary Information </B>as that term is used
      herein shall consist of the following:</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>all knowledge, data and information which Consultant may
      acquire from the documents and information disclosed to it by the Company,
      its employees, attorneys, consultants, independent contractors, clients or
      representatives whether orally, in written or electronic form or on
      electronic media including, by way of example and not by limitation, any
      products, customer lists, investor, banking or finance lists, supplier
      lists, marketing techniques, technical processes, formulae, inventions or
      discoveries (whether patentable or not), innovations, suggestions, ideas,
      reports, data, patents, trade secrets and copyrights, made or developed by
      the Company and related data and information related to the conduct of the
      business of the Company.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>Proprietary Information shall also include discussions
      with officers, directors, employees, independent contractors, attorneys,
      consultants, clients, finance sources, customers or representatives and
      the fact that such discussions are taking place.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>Proprietary Information shall not be directly or
      indirectly disclosed to any other person without the prior written
      approval of the Company, unless such disclosure is necessary for
      Consultant to perform the Services.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD>
      <P align=justify>Proprietary Information may not be used during the period
      of this Agreement nor thereafter, for the betterment of any other
      commercial enterprise, company, project or person without the prior
      written approval of the Company.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD>
      <P align=justify>Proprietary Information shall NOT include matters of
      general public knowledge, information posted on any of the Company&#146;s
      websites or in any Company public regulatory filing; information legally
      received or obtained by Consultant from a third party or parties without a
      duty of confidentiality, and information independently known or developed
      by Consultant without the assistance of the
Company.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">8.6 </TD>
    <TD>
      <P align=justify>Consultant shall well and faithfully serve the Company or
      any subsidiary as aforesaid during the continuance of this Agreement and
      use its commercially reasonable efforts to promote the interests of the
      Company. At all times Consultant will maintain a high degree of
      professionalism and integrity in performing the Services. Consultant
      reserves the right to refuse any request from the Company which may, in
      its reasonable opinion, violate either Federal or State Laws in either the
      United States or Canada.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.7 </TD>
    <TD>
      <P align=justify>The Company acknowledges and agrees that Consultant is an
      independent contractor and will have and will continue to have financial,
      management and business interests in other companies. The Company agrees
      that Consultant will continue to devote time to such outside
    interests.</P></TD></TR></TABLE>
<P align=center>- 5 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_6></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">8.8 </TD>
    <TD>
      <P align=justify>The Services to be performed by Consultant pursuant
      hereto are personal in character, to be performed by Mr. Peter Barsoom,
      and neither this Agreement nor any rights or benefits arising thereunder
      are assignable by Consultant without the previous written consent of the
      Company.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.9 </TD>
    <TD>
      <P align=justify>Previous written agreements between the parties hereto
      are unaffected by this Agreement and any notice of cancellation, default
      or any other circumstances related to this Agreement shall not impose upon
      nor affect prior agreements in any manner in respect of any such previous
      agreements.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">8.10 </TD>
    <TD>
      <P align=justify>Every provision of this Agreement is intended to be
      severable. If any term or provision hereof is illegal or invalid for any
      reason whatsoever, such illegality or invalidity shall not affect the
      validity of the remainder of the provisions of this Agreement.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.11 </TD>
    <TD>
      <P align=justify>This Agreement is being delivered and is intended to be
      managed from the Province of British Columbia and shall be construed and
      enforced in accordance with, and the rights of the parties shall be
      governed by, the laws of such Province. Similarly no provision within this
      contract is deemed valid should it conflict with the current or future
      laws of the United States of America or current or future regulations set
      forth by the United States Securities and Exchange Commission, the British
      Columbia Securities Commission, or the Ontario Securities Commission. This
      Agreement may not be changed orally, but only by an instrument in writing
      signed by the party against whom or which enforcement of any waiver,
      change, modification or discharge is sought.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.12 </TD>
    <TD>
      <P align=justify>This Agreement and the obligations of the Company herein
      are subject to all applicable laws and regulations in force at the local,
      State, Province, and Federal levels in both Canada and the United
      States.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.13 </TD>
    <TD>
      <P align=justify>The securities referred to herein will not be or have not
      been registered under the United States Securities Act of 1933, as
      amended, and may not be offered or sold in the United States absent
      registration or an applicable exemption from registration requirements.
      Any and all Warrants, restricted common share award or stock option awards
      will be in compliance with all applicable regulations in the USA and
      Canada. The securities issued will be subject to a hold period in Canada
      of not less than four months and one day, or for any resales possible into
      the USA under Rule 144, not less than six months and one day. Hold periods
      may be longer if regulations so stipulate.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">8.14 </TD>
    <TD>
      <P align=justify>Consultant understands that as a publicly traded entity,
      the Company has certain transparency obligations to its shareholders,
      stock exchanges, and other regulatory bodies, and has legal obligations to
      disclose Consultant&#146;s initial and ongoing relationship with the Company
      during the normal course of business. Consultant understands and agrees
      that its name and Mr. Peter Barsoom&#146;s likeness could be announced and
      widely circulated with regards to his role with the Company. His name will
      be disseminated through such avenues as press releases, websites, or other
      media; and in personal meetings and appearances and public events;
      provided however, Consultant shall pre-approve the same in each
    case.</P></TD></TR></TABLE>
<P align=center>(signature page to follow) </P>
<P align=center>- 6 - </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_7></A>
<P align=center><IMG
src="exhibit10-1x7x1.jpg"
border=0>&nbsp;<BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</P>
</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Announces Exercises of Existing Warrants, Enters
Consulting Agreement </B></P>
<P align=justify>Kelowna, British Columbia &#150; May 28, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) announces warrant
transactions.</P>
<P align=justify>Lexaria announces it has received US$63,000<B> </B>from the
exercise of warrants previously granted. The Company has received for exercise a
total of 450,000 warrants with an exercise price of US$0.14, previously granted.
The warrant exercises are by third parties who are neither an officer nor a
director of the Company. </P>
<P align=justify>No commissions or placement fees have been paid related to the
funds received from these warrants exercised. Proceeds will be used for general
corporate purposes.</P>
<P align=justify><B>The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. </B>Separately, Lexaria
also announces it has entered into a three-year consulting contract for the cost
of a one-time payment of US$500 and the granting of 250,000 warrants expiring
three years after issuance with an equity exercise price of US$1.55. No shares
are being issued at this time. Services to be provided include customer
relations and introductions, participation at industry events, and communication
of Lexaria&#146;s technology to other prospective customers.</P>
<P align=justify><B>About Lexaria </B></P>
<P align=justify>Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH<SUP>TM </SUP>delivery technology. Lexaria&#146;s technology provides
increases in intestinal absorption rates; more rapid delivery to the
bloodstream; and important taste-masking benefits, for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. <U>www.lexariabioscience.com </U></P>
<P align=justify>For regular updates, connect with Lexaria on Twitter (<U>https://twitter.com/lexariacorp) </U>and on Facebook
<U>http://tinyurl.com/y8vzcaam </U></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U>www.NetworkNewsWire.com
</U><BR></P>
<hr style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noshade size=5>
<a name="page_2"></a>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements,
including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks
and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are
not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any
other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&amp;D is often unpredictable and unanticipated results could
emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&amp;D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that
any of Lexaria&rsquo;s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).
Lexaria Energy Foods, Ambarii, DehydraTECH<SUP>TM</SUP> technology and ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or prevent any disease. </P>
<P align="justify">
<I>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </I></P>

<HR noshade align="center" width="100%" size=5 color="black">
</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>exhibit99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.2 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 99.2 </B></P>
<P align=center><B>Lexaria Bioscience Corp. Structures Nicotine &amp;
Pharmaceutical Subsidiaries </B></P>
<P align=justify>Kelowna, British Columbia &#150; May 31, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug delivery
platform innovator, announces that, subject to ongoing legal and tax analysis,
it intends to create two wholly-owned subsidiaries that will respectively hold
the intellectual property (&#147;IP&#148;) related to, in the case of the first
subsidiary, the improved processing and combustion-free delivery of nicotine and
nicotine analogs and, in the case of the second subsidiary, delivery of
non-steroidal anti-inflammatory drugs (&#147;NSAIDs&#148;), phosphodiesterase (&#147;PDE5&#148;)
inhibitors and other active pharmaceutical ingredients.</P>
<P align=justify>This proposed structure more suitably reflects the distinct
customer bases and business applications for each subsidiary, thereby allowing
the Company to focus its future research and consider financing structures and
industry partnerships specifically optimized to each. It is expected that
Lexaria&#146;s patented DehydraTECH<SUP>TM</SUP> technology will be utilized by both
subsidiaries.</P>
<P align=justify>Lexaria recently announced lab test results related to delivery
of nicotine through the gastrointestinal tract and superior nicotine absorption
in animal blood plasma with two particularly significant findings: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1) </TD>
    <TD>
      <P align=justify>Speed of onset &#150; as much nicotine delivered to the
      bloodstream in 15 minutes with the Lexaria technology vs. nearly 3 hours
      in the control group.</P></TD></TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2) </TD>
    <TD>
      <P align=justify>Bioavailability &#150; approximately 560% more nicotine into
      brain tissue than the control formulation.</P></TD></TR></TABLE>
<P align=justify>These discoveries have led to increased and ongoing dialogue
with leading nicotine industry participants regarding the possible utilization
of Lexaria&#146;s technology. Lexaria believes that these organizational changes
could enable significant increases in shareholder value while meeting the
diverse needs of providing services to different industry sectors. </P>
<P align=justify>Separately, the Company announces that pursuant to existing
stock option plans, it has granted stock options to directors, officers,
employees and consultants that enable the option holders to purchase up to
1,725,000 common shares of the Company at a price of US$1.53 for a period of
five years, vesting immediately. </P>
<P align=justify><B>The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. </B></P>
<P align=justify><B>About Lexaria </B></P>
<P align=justify>Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for applications of its
DehydraTECH<SUP>TM</SUP> delivery technology. Lexaria&#146;s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, NSAIDs, PDE5 inhibitors, nicotine and other
molecules. www.lexariabioscience.com </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A><IMG src="tw.jpg" border=0> For
regular updates, connect with Lexaria on Twitter
(https://twitter.com/lexariacorp)<BR>
<IMG src="fb.jpg" border=0>&nbsp;and on
Facebook http://tinyurl.com/y8vzcaam
<br>
FOR FURTHER INFORMATION PLEASE CONTACT:<BR>
Lexaria Bioscience
Corp.<BR>
Alex Blanchard, Communications Manager <BR>
(778) 796-1897 <BR>
Or
<BR>
NetworkNewsWire (NNW) <BR>
www.NetworkNewsWire.com <BR>
<P align=justify>FORWARD-LOOKING STATEMENTS </P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing cannabinoids or any
other active ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture, technology licensing
pursuit, patent application or allowance, consumer study, or any initiative will
be pursued, or if pursued, will be successful. There is no assurance that any of
Lexaria&#146;s postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or in any part.
There is no assurance that ongoing dialogue with leading nicotine industry
participants will lead to any benefit to the Company. No statement herein has
been evaluated by the Food and Drug Administration (FDA). Lexaria-associated
products are not intended to diagnose, treat, cure or prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>exhibit10-1x7x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit10-1x7x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1" .. I4# 2(  A$! Q$!_\0
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M[HDD"D_3- %BBHQ-$3(!*F8OOC</DXSSZ<5&U]9J\2-=0!I@#&#(,N#T(]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !6+>>%-'O;N2ZN+9FEE.782N,GZ UM44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB#Z*/ZY/O3[2W^SQ89S)*W,DA&"[>O\ @.PIE]?16,(>3+.[!(XU^](QZ**
M(Q+%I[B*6=B)I (58EV&<#'<XSW/3/TI]S?PV\ZVX/F7+KN6%>N/4]@/<U6L
M[5K1)M0U*0/<D%W(Y6)1_"OT'?OSZU-;62>27O(XY)I&\Q]P#!3V ]@,#\,]
MZ (+J-Y%7[0T<TTK 10#_5*>N2/XL=>?08 )K0MX%MH5B3) R23U8GDD^Y/-
M8WV:U::*YB@BCNIV1X2J[3'"I!)/ID9S_O!36@=4@=BMMFX(ZLG^K7ZN>/P&
M3[4 7JJ2327#F&U.%'#S]E]E]3^@_2HXX_MQW3W*2(.#! WR?\"/5OT'M5Y5
M"J%4 *!@ =!0 V*-(8UCC&U%& *?110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 4=6:,6JI,P2"614E9C@!3U!]C]W
M\:KWOB'3K6UD>*YBF=1A41@>>V3T ]SQ6J0&!! (/4&N;UK47L=0B2U@B-K9
M*LMW^['RJS;1CT(&X_2@"OH]UI]O;LMUK5DAE9I)EBN%W2.W4E^,>@"XZ=36
MS%K.BQ0XBOK-(E. 5D4+GZ^M6?M5N=06S"9E:$S X&W;D#K^-8-QK%OJ$UDL
M-AYEO/!-*'DC7*E3CCGC'.?J* -&]U_3UA58=0M@\O"R&5=J#NV3QQV'?\R*
MKZYI%K=VQBOK9K:.%H@$F7Y#E<<9]!C_ /73?#^KV;65C#):-;-<1;Q(80D<
MCA<M@_F>?2KMKK=E<S0H+>>..X.()I(L)*>O!]^V<9H CD\26$@VP7]E$3_'
M-.I _P" @Y/Z5'_:6C)=02-JEI*RY+2O.N[.,#O@#D\#N1Q38]?@O3:26T%Q
M%%+,$#26XQ-\KG"G/8KU_P :GAUVWDODM)=/N[>1D+YFB4!5 Y)P3@=LT 32
MZYHDD;1R:G9E77!'GKR#^-9%_K0U%)K:+5]-L86W(9?.61BO3('O^&/>M2WU
MRQGDC#0S0QS F&::,*DH SP?ISSCBJ?]N"XU72X;:VEBM[IGRTL( E4(2"I^
MN/3K0!5M/[%^9]2UJPNYF !?> 2!TZL<?\!VUHPW_AF%@R7>G[P,;VE5F_[Z
M)S3?$-])93VL0F2RMI=WF79AWA2,87T&<GD^E1Q7TT=D'ENK>>-KJ*.*Z@C5
MO-5B 00#@'G&?TH LRZGX=EVF6\TYB/NDR)D?0]JDBUO1H4"#5[9E_AWW 8@
M?4G)_&H9O$-C$Q/V:X>$3" 3I$#&7SC .?7OTXH;Q#8I+(K6UP(HI_L\D_E#
MRT?..3GIG^= %IM=TE" ^I6JDC.&E4&D_P"$AT;_ *"MG_W^7_&H9M;LH)G5
MK6?R4E$3W B'EJY(&"<YZD#.*KP:\@DOQ=6CJ(;D00A(P6D) PO7ENI],4 7
MO^$@T;_H*V?_ '^7_&C_ (2'1O\ H*V?_?Y?\:KR:_8PVTLLUM/&\,B1O"T0
M\P%ONG&>0?8U)%K-F\%Y++;RVYLU#RI,@#8(R,#/?!H D_X2#1O^@K9_]_U_
MQH_X2#1\9_M2SQ_UV7_&KL6R2)'\K;N .UE&1GL?>G[$_N+^5 &?_P )!H^,
M_P!J6>/^NR_XT?\ "0Z-_P!!6S_[_+_C6AL3^XOY4GEI_<7\J *'_"0:-_T%
M;/\ [_+_ (T?\)!HW_05L_\ O\O^-:'EI_<7\J/+3^XOY4 9_P#PD&C?]!6S
M_P"_Z_XT?\)!H^,_VI9X_P"NR_XUH;$_N+^5&Q/[B_E0!G_\)!H^,_VI9X_Z
M[+_C1_PD.C?]!6S_ ._R_P"-:&Q/[B_E2>6G]Q?RH H?\)!HW_05L_\ O\O^
M-36NK:=>2^5:WUO-)C.R.0,<?05:\M/[B_E0%53D*!]!0 ZBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9)!/;/)!<A"S2#:1L8^H[>M/N51-.TV#5M*>YL5LT^=(F:2&4 9! Y Q^HH
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MB'#(?454/AW1SC_B7P<>U)_PC>C9S_9T&?I0!/;Z;'%*LLTLMU,OW7F;.WZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4G3I2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
2444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tw.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  Z #$# 2(  A$! Q$!_\0
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A45HZTVK7,%A:*=^48B! %4  >@IU+161T6L%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>fb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fb.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  V #,# 2(  A$! Q$!_\0
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M6!0L3'Y1C%0VY83ILSNSQBM913@0OB/3Z*!THK@L=($9&#7F^J6;66H2P$<
MY4^W:O2*SM8TB'4XOF^650=KBM*4^5D3CS(\]&0>M=AXB!'AR$\\%?Y5S5WI
M=Y9.5E@? Z,!D$4V2ZNYX5BDDD=%Z*><5U37-9IF2=MRKTQ6OX9LC=ZFKD9C
MB^8GUJ+3]#O;YUQ$4CSDNW%=QI]A#I]NL,*\#J>Y-35JI*R'"-]2SR**6BN*
CQN%%%%, (!&",CWJ,6\(;<(8P?4**** )**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
